1. Scrip
  2. >>Business

Teva Appoints New Global Generics Head Amid Massive Integration

 
• By Sukaina Virji

Just months after Teva closed the $40.5bn acquisition of Allergan Generics, the company said the man expected to lead the integration, Siggi Olafsson, will step down and be succeeded by Dipankar Bhattacharjee.

Teva Pharmaceutical Industries Ltd. has appointed Dipankar Bhattacharjee as president and CEO of its global generic medicines group, effective immediately, and he will be tasked with an enormous job: overseeing the integration of Allergan PLC’s generic drug business.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies